• 1
    Kainu T, Juo SH, Desper R, Schaffer AA, Billanders E, Rozenblum E, Freas-Lutz D, Weaver D, Stephan D, Bailey-Wilson J, Kallioniemi OP, Tirkkonen M, et al. Somatic deletions in hereditary breast cancers implicate 13q21 as a putative novel breast cancer susceptibility locus. Proc Natl Acad Sci USA 2000; 97: 96038.
  • 2
    Antoniou AC, Gayther SA, Stratton JF, Ponder BA, Easton DF. Risk models for familial ovarian and breast cancer. Genet Epidemiol 2000; 18: 17390.
  • 3
    Robson M. Are BRCA1- and BRCA2-associated breast cancers different? Prognosis of BRCA1-associated breast cancer. J Clin Oncol 2000; 18: 113S8S.
  • 4
    Vasen HF, Haites NE, Evans DG, Steel CM, Moller P, Hodgson S, Eccles D, Morrison P, Stoppa-Lyonnet D, Chang-Claude J, Caligo M. Current policies for surveillance and management in women at risk of breast and ovarian cancer: a survey among 16 European family cancer clinics. European Familial Breast Cancer Collaborative Group. Eur J Cancer 1998; 34: 19226.
  • 5
    Moller P, Reis MM, Evans G, Vasen H, Haites N, Anderson E, Steel CM, Apold J, Lalloo F, Maehle L, Preece P, Gregory H, et al. Efficacy of early diagnosis and treatment in women with a family history of breast cancer. European Familial Breast Cancer Collaborative Group. Dis Markers 1999; 15: 17986.
  • 6
    Davies JF, Redmond EK, Cox MC, Lalloo FI, Elles R, Evans DGR. 2157delG: a frequent mutation in BRCA2 missed by PTT. J Med Genet 2000; 37: e42.
  • 7
    Moller P, Borg A, Heimdal K, Apold J, Vallon-Christersson J, Hovig E, Maehle L. The BRCA1 syndrome and other inherited breast or breast–ovarian cancers in a Norwegian prospective series. Eur J Cancer 2001; 37: 102732.
  • 8
    Lakhani SR, Gusterson BA, Jacquemier J, Sloane JP, Anderson TJ, van de Vijver MJ, Venter D, Freeman A, Antoniou A, McGuffog L, Smyth E, et al. The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2. Clin Cancer Res 2000; 6: 7829.
  • 9
    Stoppa-Lyonnet D, Ansquer Y, Dreyfus H, Gautier C, Gauthier-Villars M, Bourstyn E, Clough KB, Magdelenat H, Pouillart P, Vincent-Salomon A, Forugquet A, Asselain B. Familial invasive breast cancers: worse outcome related to BRCA1 mutations. J Clin Oncol 2000; 18: 40539.
  • 10
    Foulkes WD, Chappuis PO, Wong N, Brunet JS, Vesprini D, Rozen F, Yuan ZQ, Pollak MN, Kuperstein G, Narod SA, Bein LR. Primary node negative breast cancer in BRCA1 mutation carriers has a poor outcome. Ann Oncol 2000; 11: 30713.
  • 11
    Rebbeck TR. Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2000; 18: 100S3S.
  • 12
    Narod SA, Brunet JS, Ghadirian P, Robson M, Heimdal K, Neuhausen SL, Stoppa-Lyonnet D, Lerman C, Pasini B, de los Rios P, Weber B, Lynch H, et al. Hereditary Breast Cancer Clinical Study Group. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Lancet 2000; 356: 187681.
  • 13
    Li CI, Malone KE, Weiss NS, Daling JR. Tamoxifen therapy for primary breast cancer and risk of contralateral breast cancer. J Natl Cancer Inst 2001; 93: 9635.
  • 14
    Verhoog LC, Brekelmans CT, Seynaeve C, Meijers-Heijboer EJ, Klijn JG. Contralateral breast cancer risk is influenced by the age at onset in BRCA1-associated breast cancer. Br J Cancer 2000; 83: 3846.
  • 15
    Levy-Lahad E, Krieger M, Gottfeld O, Renbaum P, Klein G, Eisenberg S, Lahad A, Kaufman B, Catane R. BRCA1 and BRCA2 mutation carriers as potential candidates for chemoprevention trials. J Cell Biochem Suppl 2000; 34: 138.
  • 16
    Eeles RA, Powles TJ. Chemoprevention options for BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2000; 18: 93S9S.
  • 17
    Møller P, Mæhle L, Heimdal K, Dorum A, Apold J, Engebretsen LF, Kaurin RM, Jørgensen OG, Helgerud P, Qvist H, Bjørndal H, Kullmann G, et al. Prospective findings in breast cancer kindreds. Annual incidence rates according to age, stage at diagnosis, mean sojourn time, and incidence rates for contralateral cancer. Breast 1998; 7: 559.
  • 18
    Moller P, Evans G, Haites N, Vasen H, Reis MM, Anderson E, Apold J, Hodgson S, Eccles D, Olsson H, Stoppa-Lyonnet D, Chang-Claude J, et al. Guidelines for follow-up of women at high risk for inherited breast cancer: consensus statement from the Biomed 2 Demonstration Programme on Inherited Breast Cancer. Dis Markers 1999; 15: 20711.
  • 19
    Pharoah PD, Easton DF, Stockton DL, Gayther S, Ponder BA. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group. Survival in familial, BRCA1-associated, and BRCA2-associated epithelial ovarian cancer. Cancer Res 1999; 59: 86871.
  • 20
    Hartmann LC, Schaid DJ, Woods JE, Crotty TP, Myers JL, Arnold PG, Petty PM, Sellers TA, Johnson JL, McDonnell SK, Frost MH, Jenkins RB. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 1999; 340: 7784.
  • 21
    McDonnell SK, Schaid DJ, Myers JL, Grant CS, Donohue JH, Woods JE, Frost MH, Johnson JL, Sitta DL, Slezak JM, Crotty TB, Jenkins RB, et al. Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer. J Clin Oncol 2001; 19: 393843.
  • 22
    Verhoog LC, Brekelmans CT, Seynaeve C, Van den Bosch LM, Dahmen G, Geel AN, Tilanus-Linthorst MM, Bartels CC, Wagner A, van den Ouweland A, Devilee P, Meijers-Heijboer EJ, et al. Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet 1998; 351: 31621.